Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
RADX has basic price and filing data (45% intelligence coverage), but earnings analysis, financial metrics, and proprietary signals are still building. Explore a peer with deeper coverage below.
Deeper coverage nearby
Intelligence coverage: 45%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 50% · prior close shown (market closed)
Limited proprietary earnings coverage for RADX yet — signals will sharpen as filings and earnings are ingested.
Pipeline evidence · 68d ago
Updated
What happened recently for Radiopharm Theranostics Ltd (RADX) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$1.63
Market cap
$3.84B
Profitable
—
Net income
—
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Radiopharm Theranostics Ltd — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Radiopharm Theranostics Ltd through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
The tools to read, edit, and deliver on the genome are maturing faster than the market prices in.
The edge in healthcare no longer belongs to the biggest drug pipelines — it belongs to the most targeted ones.